SPARTAN v1.0
Research type
Research Study
Full title
A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients with Immunoglobulin A Nephropathy
IRAS ID
257450
Contact name
Michelle Muessel
Contact email
Sponsor organisation
University of Leicester
Eudract number
2018-002012-27
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This is an exploratory open-label study, to examine the response to sparsentan treatment as a potential first-line treatment in patients newly diagnosed with IgAN (Immunoglobulin A Nephropathy). IgAN is a condition that results in kidney inflammation that, over time, may decrease the kidneys' ability to filter wastes from the blood. Participants who are eligible for the study will receive sparsentan and undertake a number of study visits, at approximately 4-week intervals for a variety of tests and treatment with the study medication. This study will be unblinded and all participants will receive treatment with sparsentan.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
19/EM/0334
Date of REC Opinion
9 Dec 2019
REC opinion
Favourable Opinion